Overview

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).
Phase:
Phase 2
Details
Lead Sponsor:
Arrevus Inc.
Cempra Inc
Treatments:
Fusidic Acid
Linezolid